MCID: FBR009
MIFTS: 48

Fibrous Dysplasia

Categories: Bone diseases, Rare diseases

Aliases & Classifications for Fibrous Dysplasia

MalaCards integrated aliases for Fibrous Dysplasia:

Name: Fibrous Dysplasia 12 74 52 54 15 71 32
Fibrous Dysplasia of Bone 52

Classifications:



External Ids:

Disease Ontology 12 DOID:0080031
ICD10 32 M85.0
UMLS 71 C0259779

Summaries for Fibrous Dysplasia

NIH Rare Diseases : 52 Fibrous dysplasia is a skeletal disorder that is characterized by the replacement of normal bone with fibrous bone tissue . It may involve one bone (monostotic ) or multiple bones (polyostotic ). Fibrous dysplasia can affect any bone in the body. The most common sites are the bones in the skull and face, the long bones in the arms and legs, the pelvis, and the ribs. Though many people with this disorder do not have any symptoms, others may have bone pain, abnormally shaped bones (deformities), or an increased risk of fractures (broken bones). The problems a person experiences depend on which bones are affected, and may arise from compression and displacement of adjacent structures to the lesions. For example, the legs can be of different lengths, leading to a limp, the bones of the sinuses can be affected, leading to chronic sinus congestion or headache. This condition can occur alone or as part of a genetic disorder , such as McCune-Albright syndrome . While there is no cure for fibrous dysplasia, the symptoms can be treated. Medications known as bisphosphonates can reduce pain and surgery may be used to treat fractures or to correct misshapen bones.

MalaCards based summary : Fibrous Dysplasia, also known as fibrous dysplasia of bone, is related to fibrous dysplasia/mccune-albright syndrome and osteofibrous dysplasia. An important gene associated with Fibrous Dysplasia is GNAS (GNAS Complex Locus), and among its related pathways/superpathways are TGF-Beta Pathway and Akt Signaling. The drugs Dopamine and Methamphetamine have been mentioned in the context of this disorder. Affiliated tissues include bone, pituitary and thyroid, and related phenotypes are growth/size/body region and immune system

Disease Ontology : 12 A bone remodeling disease that results in the destruction of normal bone and replacing it with fibrous bone tissue.

Wikipedia : 74 Fibrous dysplasia is a disorder where normal bone and marrow is replaced with fibrous tissue, resulting... more...

Related Diseases for Fibrous Dysplasia

Diseases related to Fibrous Dysplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 505)
# Related Disease Score Top Affiliating Genes
1 fibrous dysplasia/mccune-albright syndrome 34.2 PRL GNAS GH1
2 osteofibrous dysplasia 33.2 SPP1 SPARC GNAS BGLAP
3 mccune-albright syndrome 32.3 SST SPARC PTHLH PRL IGF1 IBSP
4 ossifying fibroma 31.4 GNAS FGF23 CDC73
5 rickets 30.7 SPP1 IBSP FGF23 BGLAP
6 gigantism 30.6 PRL GHRH GH1
7 osteomalacia 30.4 PTHLH FGF23 CALCA BGLAP
8 secondary hyperparathyroidism 30.4 FGF23 CALCA BGLAP
9 hypophosphatemia 30.4 SPP1 PTHLH FGF23 BGLAP
10 endosteal hyperostosis, autosomal dominant 30.3 SH3BP2 IBSP GNAS
11 hyperostosis 30.3 SPP1 IGF1 FGF23
12 hyperparathyroidism 30.3 PTHLH FGF23 CDC73 CALCA BGLAP
13 meningioma, familial 30.3 TP53 SST PRL IGF1
14 oncogenic osteomalacia 30.3 PTHLH FGF23
15 chromophobe adenoma 30.2 PRL GH1
16 central precocious puberty 30.2 IGF1 GH1
17 renal osteodystrophy 30.1 FGF23 CALCA BGLAP
18 bone osteosarcoma 30.1 TP53 SPARC BGLAP
19 osteonecrosis 30.1 RUNX2 IGF1 BGLAP
20 empty sella syndrome 30.0 PRL IGF1 GH1
21 pituitary tumors 30.0 SST PRL IGF1 GNAS GH1
22 hyperthyroidism 30.0 SST PRL IGF1 GNAS GH1 CALCA
23 amenorrhea 29.9 PRL IGF1 BGLAP
24 connective tissue benign neoplasm 29.9 TP53 GNAS CDC73
25 acromegaly 29.8 SST PRL IGF1 GNAS GHRH GH1
26 calcinosis 29.8 SPP1 SPARC FGF23 CALCA
27 pituitary adenoma 29.8 SST PRL IGF1 GNAS GHRH GH1
28 enchondromatosis, multiple, ollier type 29.7 RUNX2 PTHLH GNAS
29 neurofibromatosis, type ii 29.7 PRL IL6 IGF1
30 pseudopseudohypoparathyroidism 29.7 PTHLH GNAS GHRH
31 scoliosis 29.6 RUNX2 IL6 IGF1 GH1 BGLAP
32 thyroiditis 29.5 PRL IL6 CALCA
33 brittle bone disorder 29.5 SPP1 SPARC RUNX2 IBSP CALCA BGLAP
34 neuroendocrine tumor 29.5 SST IGF1 GHRH CALCA
35 goiter 29.5 SST PRL IGF1 GNAS CALCA BGLAP
36 hypoparathyroidism 29.4 PTHLH GNAS FGF23 CALCA BGLAP
37 conn's syndrome 29.4 SST PRL IGF1 GNAS GHRH GH1
38 adenoma 29.4 TP53 SST PRL IGF1 GNAS GH1
39 end stage renal failure 29.4 PRL IL6 CALCA BGLAP
40 hormone producing pituitary cancer 29.3 SST PRL IGF1 GNAS GHRH
41 carney complex variant 29.3 SST PRL IGF1 GNAS GHRH
42 insulin-like growth factor i 29.2 SST PRL IGF1 GHRH GH1 BGLAP
43 osteitis fibrosa 29.2 IL6 GNAS FGF23 CDC73 CALCA BGLAP
44 paget's disease of bone 29.2 SPARC PTHLH IL6 IBSP CALCA BGLAP
45 esophagitis 29.2 TP53 POSTN IL6
46 hyperglycemia 29.1 SST IL6 IGF1 GH1
47 pituitary gland disease 29.0 SST PRL IGF1 GNAS GHRH GH1
48 pseudohypoparathyroidism 29.0 PTHLH PRL IGF1 GNAS CALCA BGLAP
49 parathyroid adenoma 29.0 PTHLH IGF1 GNAS CDC73 CALCA BGLAP
50 pituitary adenoma, prolactin-secreting 28.9 SST PTHLH PRL IGF1 GNAS GH1

Graphical network of the top 20 diseases related to Fibrous Dysplasia:



Diseases related to Fibrous Dysplasia

Symptoms & Phenotypes for Fibrous Dysplasia

MGI Mouse Phenotypes related to Fibrous Dysplasia:

45 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.41 CDC73 FGF23 GHRH GNAS IBSP IGF1
2 immune system MP:0005387 10.4 CDC73 FGF23 GHRH GNAS IBSP IGF1
3 homeostasis/metabolism MP:0005376 10.39 CDC73 FGF23 GHRH GNAS IGF1 IL6
4 behavior/neurological MP:0005386 10.36 CDC73 GHRH GNAS IL6 PFKFB4 POSTN
5 hematopoietic system MP:0005397 10.34 CDC73 FGF23 GNAS IBSP IGF1 IL6
6 endocrine/exocrine gland MP:0005379 10.29 CDC73 FGF23 GHRH GNAS IGF1 IL6
7 cardiovascular system MP:0005385 10.27 CDC73 FGF23 GNAS IGF1 IL6 POSTN
8 craniofacial MP:0005382 10.27 CDC73 GNAS IBSP POSTN PTHLH RUNX2
9 integument MP:0010771 10.26 CDC73 FGF23 GNAS IGF1 IL6 PRL
10 digestive/alimentary MP:0005381 10.21 CDC73 FGF23 IBSP IL6 PTHLH RUNX2
11 adipose tissue MP:0005375 10.19 CDC73 GHRH GNAS IGF1 IL6 POSTN
12 limbs/digits/tail MP:0005371 10.16 FGF23 GNAS IBSP IGF1 POSTN PTHLH
13 liver/biliary system MP:0005370 10.13 CDC73 GHRH GNAS IL6 PRL PTHLH
14 nervous system MP:0003631 10.1 CDC73 GHRH GNAS IGF1 IL6 PRL
15 neoplasm MP:0002006 10.07 CDC73 GNAS IGF1 IL6 POSTN PRL
16 muscle MP:0005369 10.06 CDC73 GNAS IGF1 IL6 POSTN RUNX2
17 reproductive system MP:0005389 9.93 CDC73 FGF23 GHRH IGF1 IL6 PFKFB4
18 renal/urinary system MP:0005367 9.86 CDC73 FGF23 GNAS IGF1 IL6 PTHLH
19 respiratory system MP:0005388 9.65 CDC73 FGF23 GNAS IGF1 IL6 PTHLH
20 skeleton MP:0005390 9.5 CDC73 FGF23 GHRH GNAS IBSP IGF1

Drugs & Therapeutics for Fibrous Dysplasia

Drugs for Fibrous Dysplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
3 Sympathomimetics Phase 4
4 Neurotransmitter Agents Phase 4
5 Central Nervous System Stimulants Phase 4
6 Dopamine Agents Phase 4
7 Autonomic Agents Phase 4
8 Dopamine Uptake Inhibitors Phase 4
9 Adrenergic Agents Phase 4
10
Etidronic acid Approved Phase 2, Phase 3 2809-21-4, 7414-83-7 3305
11
Risedronate Approved, Investigational Phase 2, Phase 3 105462-24-6 5245
12
Zoledronic Acid Approved Phase 3 118072-93-8 68740
13
Calcium Approved, Nutraceutical Phase 2, Phase 3 7440-70-2 271
14 Calcium, Dietary Phase 2, Phase 3
15 calcium channel blockers Phase 2, Phase 3
16 Diphosphonates Phase 3
17 Anesthetics Phase 3
18 Pharmaceutical Solutions Phase 3
19 Analgesics Phase 3
20
Alendronate Approved Phase 2 121268-17-5, 66376-36-1 2088
21
Testolactone Approved, Investigational Phase 2 968-93-4 13769
22
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
23
Fulvestrant Approved, Investigational Phase 2 129453-61-8 104741 17756771
24
Denosumab Approved Phase 2 615258-40-7
25 Aromatase Inhibitors Phase 2
26 Steroid Synthesis Inhibitors Phase 2
27 Phosphodiesterase 4 Inhibitors Phase 1, Phase 2
28 Hormones Phase 2
29 Hormone Antagonists Phase 2
30 Estrogens Phase 2
31 Estrogen Receptor Antagonists Phase 2
32 Estrogen Antagonists Phase 2
33 Antineoplastic Agents, Hormonal Phase 2
34
Letrozole Approved, Investigational Phase 1 112809-51-5 3902
35
Histamine Approved, Investigational 51-45-6 774
36
Histamine Phosphate 51-74-1 65513
37 Fluorodeoxyglucose F18
38 Radiopharmaceuticals

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 Bioactive Glass Granules as Bone Graft Substitute in Filling Material of Bone Defects Completed NCT01304121 Phase 4
2 Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone Unknown status NCT00445575 Phase 2, Phase 3 risedronate;placebo;risedronate;placebo
3 A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome Completed NCT00017927 Phase 3 Pegvisomant
4 Non-inferiority Trial of Three Cycles of Zoledronic Acid Versus Percutaneous Thermal Ablation in Osteoid Osteoma Recruiting NCT02739555 Phase 3 Acide Zoledronique MEDAC
5 TREATMENT OF FIBROUS DYSPLASIA OF BONE WITH TOCILIZUMAB AMONG PATIENTS WHO DO NOT RESPOND TO BISPHOSPHONATES. THE TOCIDYS TRIAL. Completed NCT01791842 Phase 2 Tocilizumab;Placebo
6 A Randomized, Placebo-Controlled Trial of Alendronate in the Treatment of Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome Completed NCT00001728 Phase 2 Fosamax (Alendronate)
7 Testolactone Treatment of Girls With LHRH Analog-Resistant Precocious Puberty Due to Autonomous, Non-Neoplastic Ovarian Estrogen Secretion Completed NCT00001181 Phase 2 Testolactone
8 An Open-label Study Evaluating the Safety and Efficacy of Anastrozole™ (ARIMIDEX) in the Treatment of Precocious Puberty in Girls With McCune-Albright Syndrome Completed NCT00055302 Phase 2 Arimidex 1 mg
9 PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of Mccune-Albright Syndrome Recruiting NCT02743377 Phase 1, Phase 2
10 An Open-label, Non-Comparative Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Faslodex (Fulvestrant) in Girls With Progressive Precocious Puberty Associated With McCune-Albright Syndrome Active, not recruiting NCT00278915 Phase 2 Fulvestrant
11 An Open Label Pilot Study of Denosumab Treatment for Fibrous Dysplasia Enrolling by invitation NCT03571191 Phase 2 Denosumab;Denosumab;Denosumab
12 Effects of the Aromatase Inhibitor Letrozole on Pubertal Progression and Indices of Bone Turnover in Girls With Precocious Puberty and McCune-Albright Syndrome (MAS) Completed NCT00006174 Phase 1 Letrozole
13 Molecular Genetic Study of Suspected Cases of Osteogenesis Imperfecta Attending Assiut University Children Hospital Unknown status NCT03169192 Zoledronic Acid
14 Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia Completed NCT02868645
15 Studies on Tissues From Patients With Fibrous Dysplasia of Bone/McCune-Albright Syndrome and Other Disorders of Calcified Tissues Completed NCT00001973
16 The Influence of Bisphosphonates in the Oral Cavity in Children Completed NCT00402064
17 Evaluation and Treatment to Improve Bone Quality and Prevent Fractures by the Percutaneous Replacement of Diseased Tissue in Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome Completed NCT00001851
18 Histamine Responsiveness in Patients With McCune-Albright Syndrome Completed NCT00318097
19 Epigenetic Regulation of Activity and Severity of Fibrous Dysplasia in Bone: mirDYS Study. Recruiting NCT03838991
20 Fibrous Dysplasia, McCune-Albright Syndrome Patient Registry Recruiting NCT03231644
21 Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome Recruiting NCT00001727
22 Computer Guided Contouring of Craniofacial Fibrous Dysplasia Involving Zygoma: a Case Series Recruiting NCT03852927
23 Elucidating Mechanisms of Pain in Adolescent and Adult Fibrous Dysplasia Patients Not yet recruiting NCT04125862
24 Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome Withdrawn NCT03520153

Search NIH Clinical Center for Fibrous Dysplasia

Genetic Tests for Fibrous Dysplasia

Anatomical Context for Fibrous Dysplasia

MalaCards organs/tissues related to Fibrous Dysplasia:

40
Bone, Pituitary, Thyroid, Skin, Brain, Breast, Bone Marrow

Publications for Fibrous Dysplasia

Articles related to Fibrous Dysplasia:

(show top 50) (show all 3693)
# Title Authors PMID Year
1
GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma. 54 61
19287459 2009
2
[Abnormal expression of c-myc, p53, p16 protein and GNAS1 gene mutation in fibrous dysplasia]. 54 61
19575869 2009
3
[Fibrous dysplasia of bone in a young male]. 54 61
19627736 2009
4
Melorheostosis and FGF-23: is there a relationship? 54 61
18485783 2008
5
The pathology of fibrous dysplasia and the McCune-Albright syndrome. 54 61
17982387 2007
6
Fibrous dysplasia, phosphate wasting and fibroblast growth factor 23. 54 61
17982392 2007
7
GNAS transcripts in skeletal progenitors: evidence for random asymmetric allelic expression of Gs alpha. 54 61
17566083 2007
8
A sensitive mutation-specific screening technique for GNAS1 mutations in cases of fibrous dysplasia: the first report of a codon 227 mutation in bone. 54 61
17493233 2007
9
Ossifying fibroma vs fibrous dysplasia of the jaw: molecular and immunological characterization. 54 61
17334331 2007
10
Current approach to fibrous dysplasia of bone and McCune-Albright syndrome. 54 61
19308500 2007
11
McCune-Albright syndrome with acromegaly and fibrous dysplasia associated with the GNAS gene mutation identified by sensitive PNA-clamping method. 54 61
17878646 2007
12
The new bone biology: pathologic, molecular, and clinical correlates. 54 61
17103447 2006
13
Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome. 54 61
16720661 2006
14
Runx2 regulates the expression of GNAS on SaOs-2 cells. 54 61
16442859 2006
15
McCune-Albright syndrome: growth hormone and prolactin hypersecretion. 54 61
16789626 2006
16
Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. 54 61
16337659 2006
17
Skeletal changes in epidermal nevus syndrome: does focal bone disease harbor clues concerning pathogenesis? 54 61
16222671 2005
18
A highly sensitive polymerase chain reaction method detects activating mutations of the GNAS gene in peripheral blood cells in McCune-Albright syndrome or isolated fibrous dysplasia. 54 61
16264125 2005
19
Fibrous dysplasia. Pathophysiology, evaluation, and treatment. 54 61
16085630 2005
20
Fibroblast growth factor 23 and its receptors. 54 61
16076372 2005
21
Juvenile psammomatoid ossifying fibroma of the neurocranium. Report of four cases. 54 61
16028779 2005
22
FGF23 and disorders of phosphate homeostasis. 54 61
15863037 2005
23
Minireview: GNAS: normal and abnormal functions. 54 61
15331575 2004
24
FGF-23 is elevated by chronic hyperphosphatemia. 54 61
15356053 2004
25
Investigation of the GSalpha gene in the diagnosis of fibrous dysplasia. 54 61
15183415 2004
26
A novel technique based on a PNA hybridization probe and FRET principle for quantification of mutant genotype in fibrous dysplasia/McCune-Albright syndrome. 54 61
15096559 2004
27
Osteoclastogenesis in fibrous dysplasia of bone: in situ and in vitro analysis of IL-6 expression. 54 61
13678786 2003
28
FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. 54 61
12952917 2003
29
Dental characteristics of fibrous dysplasia and McCune-Albright syndrome. 54 61
12973283 2003
30
Osteomalacic and hyperparathyroid changes in fibrous dysplasia of bone: core biopsy studies and clinical correlations. 54 61
12854833 2003
31
Is McCune-Albright syndrome overlooked in subjects with fibrous dysplasia of bone? 54 61
12756386 2003
32
Craniofacial anomalies: Clinical and molecular perspectives. 54 61
12772530 2003
33
Melatonin deficiency and fibrous dysplasia: might a relation exist? 54 61
12376077 2002
34
A novel, complex heterozygous mutation within Gsalpha gene in patient with McCune-Albright syndrome. 54 61
12374458 2002
35
Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. 54 61
11588148 2001
36
Asymmetry: molecular, biologic, embryopathic, and clinical perspectives. 54 61
11471152 2001
37
Detection of c-fos expression in benign and malignant musculoskeletal lesions. 54 61
11398843 2001
38
Familial craniofacial fibrous dysplasia: absence of linkage to GNAS1 and the gene for cherubism. 54 61
11073546 2000
39
A comparative study of fibrous dysplasia and osteofibrous dysplasia with regard to Gsalpha mutation at the Arg201 codon: polymerase chain reaction-restriction fragment length polymorphism analysis of paraffin-embedded tissues. 54 61
11272890 2000
40
Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone. 54 61
10646121 2000
41
A comparative study of fibrous dysplasia and osteofibrous dysplasia with regard to expressions of c-fos and c-jun products and bone matrix proteins: a clinicopathologic review and immunohistochemical study of c-fos, c-jun, type I collagen, osteonectin, osteopontin, and osteocalcin. 54 61
10667418 1999
42
Expression of osteocalcin and its transcriptional regulators core-binding factor alpha 1 and MSX2 in osteoid-forming tumours. 54 61
10569470 1999
43
A rare case of polyostotic fibrous dysplasia assessed by bone scintigraphy with Tc-99m methylene diphosphonate (MDP). 54 61
10488486 1999
44
[Fibrous dysplasia. The clinico-therapeutic picture and new data on its etiology. A review of the literature]. 54 61
9578646 1998
45
Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation. 54 61
9403710 1997
46
Primary hyperparathyroidism-associated polyostotic fibrous dysplasia: absence of McCune-Albright syndrome mutations. 54 61
9413810 1997
47
Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. 54 61
8699958 1996
48
Activating mutations of Gs protein in monostotic fibrous lesions of bone. 54 61
8648511 1996
49
Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. 54 61
7739708 1995
50
Fibrous dysplasia mimicking a pediatric endolymphatic sac tumor. 61
31770666 2020

Variations for Fibrous Dysplasia

Expression for Fibrous Dysplasia

Search GEO for disease gene expression data for Fibrous Dysplasia.

Pathways for Fibrous Dysplasia

Pathways related to Fibrous Dysplasia according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.45 TP53 PRL IL6 IGF1 GNAS GHRH
2
Show member pathways
13.31 TP53 PFKFB4 IL6 IGF1 GNAS GHRH
3
Show member pathways
12.96 IL6 IGF1 GNAS GHRH GH1 FGF23
4
Show member pathways
12.9 TP53 SPP1 IL6 IGF1 GNAS GHRH
5 12.75 TP53 IL6 IGF1 GNAS FGF23
6
Show member pathways
12.64 TP53 SPP1 PRL IL6 IGF1 IBSP
7
Show member pathways
12.61 IL6 IGF1 GHRH GH1 FGF23
8
Show member pathways
12.57 SST IGF1 GNAS GHRH GH1
9
Show member pathways
12.32 PTHLH GNAS GHRH CALCA
10
Show member pathways
12.3 IL6 IGF1 GHRH GH1 FGF23
11
Show member pathways
12.2 TP53 IL6 IGF1 GHRH GH1 FGF23
12 12.15 TP53 RUNX2 IL6 IGF1
13 12.01 PTHLH GNAS GHRH CALCA
14 11.86 TP53 SPARC IL6 IGF1
15 11.74 TP53 PRL IL6 BGLAP
16 11.74 RUNX2 PTHLH GNAS FGF23 BGLAP
17 11.6 IL6 IGF1 GNAS GHRH GH1 FGF23
18 11.58 SPP1 IL6 IGF1 CALCA
19 11.47 SPP1 RUNX2 PTHLH IGF1 GH1
20 11.39 RUNX2 IBSP BGLAP
21 11.34 SPP1 RUNX2 FGF23 BGLAP
22 11.09 SPP1 RUNX2 IL6 IGF1 CALCA BGLAP
23 10.9 SPP1 IL6 IGF1 GNAS GHRH GH1
24 10.82 IBSP FGF23 BGLAP
25 10.69 SPP1 RUNX2 PTHLH IBSP GNAS BGLAP

GO Terms for Fibrous Dysplasia

Cellular components related to Fibrous Dysplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.83 SST SPP1 SPARC PTHLH PRL POSTN
2 extracellular space GO:0005615 9.47 SST SPP1 SPARC PTHLH PRL POSTN
3 vesicle GO:0031982 9.46 SPP1 SPARC IBSP BGLAP

Biological processes related to Fibrous Dysplasia according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 10.01 TP53 SPP1 RUNX2 IL6 IGF1 FGF23
2 negative regulation of cell proliferation GO:0008285 9.97 TP53 SST PTHLH IL6 CDC73
3 positive regulation of cell proliferation GO:0008284 9.95 RUNX2 PTHLH PRL IL6 IGF1 GHRH
4 extracellular matrix organization GO:0030198 9.91 SPP1 SPARC POSTN IBSP
5 cell-cell signaling GO:0007267 9.91 SST PTHLH GHRH CALCA
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.77 IL6 IGF1 GH1
7 cellular response to growth factor stimulus GO:0071363 9.76 SPARC IBSP BGLAP
8 response to glucocorticoid GO:0051384 9.74 SPARC IL6 BGLAP
9 response to nutrient levels GO:0031667 9.73 PRL GH1 BGLAP
10 osteoblast differentiation GO:0001649 9.73 SPP1 RUNX2 IBSP BGLAP
11 bone development GO:0060348 9.72 SPARC GNAS BGLAP
12 adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0007189 9.71 PTHLH GNAS GHRH CALCA
13 response to heat GO:0009408 9.7 SST IGF1 CALCA
14 bone mineralization GO:0030282 9.69 PTHLH IBSP BGLAP
15 biomineral tissue development GO:0031214 9.67 SPP1 IBSP BGLAP
16 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 TP53 IL6 IGF1 GH1
17 positive regulation of JAK-STAT cascade GO:0046427 9.63 PRL IL6 GH1
18 response to gravity GO:0009629 9.59 SPARC BGLAP
19 positive regulation of osteoblast differentiation GO:0045669 9.56 RUNX2 IL6 IGF1 GNAS
20 osteoblast development GO:0002076 9.5 RUNX2 PTHLH BGLAP
21 skeletal system development GO:0001501 9.35 RUNX2 PTHLH IGF1 GNAS BGLAP
22 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.33 IGF1 GHRH GH1
23 cellular protein metabolic process GO:0044267 9.1 SPP1 PRL IL6 IGF1 FGF23 CALCA

Molecular functions related to Fibrous Dysplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL6 IGF1 GH1 FGF23
2 peptide hormone receptor binding GO:0051428 9.26 PTHLH GHRH
3 hormone activity GO:0005179 9.1 SST PTHLH PRL IGF1 GH1 CALCA
4 prolactin receptor binding GO:0005148 8.96 PRL GH1

Sources for Fibrous Dysplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....